How many insider trades does FilingIQ track for EDIT?

FilingIQ tracks 354 Form 4 insider transactions for EDIT (Editas Medicine, Inc.), covering filings from Feb 8, 2015 onwards. 6 of those were filed in the last 90 days.

Are EDIT insiders net buyers or net sellers?

Across the full Form 4 history for EDIT, 20 transactions (6%) were open-market purchases and 202 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does EDIT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is EDIT in?

Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $184.50M.

EDIT insider trading

NasdaqGS Healthcare

Editas Medicine, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

354

Last 90 days

Buys / sells

6% / 57%

Market cap

$184.50M

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company website: www.editasmedicine.com

EDIT insider activity at a glance

FilingIQ has scored 354 insider transactions for EDIT since Feb 8, 2015. The most recent filing in our index is dated Mar 12, 2026.

Across the full history, 20 open-market purchases and 202 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on EDIT insider trades is 57.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live EDIT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for EDIT?: FilingIQ tracks 354 Form 4 insider transactions for EDIT (Editas Medicine, Inc.), covering filings from Feb 8, 2015 onwards. 6 of those were filed in the last 90 days.
Are EDIT insiders net buyers or net sellers?: Across the full Form 4 history for EDIT, 20 transactions (6%) were open-market purchases and 202 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does EDIT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is EDIT in?: Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $184.50M.

Methodology & sources

Every EDIT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.